

Lynch HF and Bateman-House A. Facilitating both evidence and access: Improving FDA's accelerated approval and expanded access pathways. *J Law Med Ethics*. 2020. [DOI. Opens in a new tab](#)

Chapman CR, Eckman J, and Bateman-House AS. Oversight of right-to-try and expanded access requests for off-trial access to investigational drugs. *Ethics & Human Research*. 2020. [DOI. Opens in a new tab](#).

Folkers KM, Leone S, and Caplan A. Patient advocacy organizations' information for patients on pre-approval access to investigational treatments. *BMC Res Notes*. 2019. [DOI. Opens in a new tab](#).

Chapman CR ... Bateman-House A. Single-patient expanded access requests: IRB professionals' experiences and perspectives. *AJOB Empir Bioeth*. 2019. [DOI. Opens in a new tab](#).

Chapman CR ... Bateman-House A. What compassionate use means for gene therapies. *Nature Biotechnol*. 2019. [DOI. Opens in a new tab](#).

Salgado R ... Massard C. Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology. *Eur J Cancer*. 2019. [DOI. Opens in a new tab](#).

Borysowski J ... Górski A. Expanded access: Growing importance to public health. *J Epidemiol Community Health*. 2018. [DOI. Opens in a new tab](#).

Caplan AL ... Gardner SL. Fair, just and compassionate: A pilot for making allocation decisions for patients requesting experimental drugs outside of clinical trials. *J Med Ethics*. 2018. [DOI. Opens in a new tab](#).

Folkers KM and Bateman-House A. Improving expanded access in the United States: The role of the institutional review board. *Ther Innov Regul Sci*. 2018. [DOI. Opens in a new tab](#).

Kearns L, Bateman-House A, and Caplan A. Ensuring justice in access to investigational neurological drugs. *Semin Neurol*. 2018. [DOI. Opens in a new tab](#).

Puthumana J ... Ross JS. Availability of investigational medicines through the U.S. Food and Drug Administration's expanded access and compassionate use programs. *JAMA Network Open*. 2018. [DOI. Opens in a new tab](#).

Vox F ... Caplan AL. Medical crowdfunding for scientifically unsupported or potentially dangerous treatments. *JAMA*. 2018. [DOI. Opens in a new tab](#).

Caplan A and Folkers KM. Charlie Gard and the limits of parental authority. *Hastings Cent Rep*. 2017. [DOI. Opens in a new tab](#).

Kearns L and Bateman-House A. Who stands to benefit? Right to try law provisions and implications. *Ther Innov Regul Sci*. 2017. [DOI](#). [Opens in a new tab](#).

Kimberly LL ... Bateman-House A. Pre-approval access terminology: A cause for confusion and a danger to patients. *Ther Innov Regul Sci*. 2017. [DOI](#). [Opens in a new tab](#).

Moch KI. Ethical crossroads: Expanded access, patient advocacy, and the #SaveJosh social media campaign. *Med Access @ Point Care*. 2017. [DOI](#). [Opens in a new tab](#).

Caplan AL and Ray A. The ethical challenges of compassionate use. *JAMA*. 2016. [DOI](#). [Opens in a new tab](#).

Bateman-House A ... Caplan A. Right-to-try laws: Hope, hype, and unintended consequences. *Ann Intern Med*. 2015. [DOI](#). [Opens in a new tab](#).